SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $158

Credit Suisse maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $154 to $158.

 · 
Credit Suisse maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $154 to $158.